A Better Choice for Patients Undergoing Endovascular Coil Embolization

This study has suspended participant recruitment.
(No patients enrolled until now)
Sponsor:
Information provided by (Responsible Party):
Wen-fei Tan, China Medical University, China
ClinicalTrials.gov Identifier:
NCT01722409
First received: November 3, 2012
Last updated: March 17, 2014
Last verified: October 2013
  Purpose

The investigators designed a double-blind, randomized placebo-controlled study to determine the effects of dexmedetomidine on the recovery characteristics of patients who were scheduled to undergo endovascular coil embolization.


Condition Intervention Phase
Intracranial Aneurysms
Drug: sevoflurane and 0.5 μg/kg dexmedetomidine
Drug: sevoflurane and 1 μg/kg dexmedetomidine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Sevoflurane, Laryngeal Mask Airway and Single-dose Dexmedetomidine: A Better Choice for Patients Undergoing Endovascular Coil Embolization

Resource links provided by NLM:


Further study details as provided by China Medical University, China:

Primary Outcome Measures:
  • Observing the recovery characteristics of patients who were scheduled to undergo endovascular coil embolization. [ Time Frame: At the end of the operation and 24 hours later ] [ Designated as safety issue: Yes ]
    The time from termination of the general anesthetic to the time that the patient's eyes opened. Anesthesiologists collected information on emergence agitation, postoperative nausea and vomiting for 24 hours after the surgery.


Estimated Enrollment: 30
Study Start Date: December 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: sevoflurane and saline infusion
After induction of general anesthesia, Group S received a placebo infusion of normal saline.
Experimental: sevoflurane and 0.5 μg/kg dexmedetomidine
After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
Drug: sevoflurane and 0.5 μg/kg dexmedetomidine
After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
Other Name: DEX1
Experimental: sevoflurane and 1 μg/kg dexmedetomidine
After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
Drug: sevoflurane and 1 μg/kg dexmedetomidine
After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
Other Name: DEX2

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:18-65 years old ASA I or ASA II patients undergoing ECE treatment for intracranial aneurysms were included.

Exclusion Criteria:Patients were excluded based on the following parameters: older than 65 yrs, a history of mental illness, recent use of sedatives or analgesics and with sensation.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01722409

Locations
China, Liaoning
Wen-fei Tan
Shenyang, Liaoning, China, 110001
Sponsors and Collaborators
China Medical University, China
Investigators
Study Chair: Hong Ma, M.D.,PhD. Dept. of Anesthesiology, the First Hospital of CMU
  More Information

No publications provided

Responsible Party: Wen-fei Tan, Associate professor, China Medical University, China
ClinicalTrials.gov Identifier: NCT01722409     History of Changes
Other Study ID Numbers: 20121009
Study First Received: November 3, 2012
Last Updated: March 17, 2014
Health Authority: China: Ethics Committee

Keywords provided by China Medical University, China:
dexmedetomidine, endovascular coil embolization

Additional relevant MeSH terms:
Intracranial Aneurysm
Aneurysm
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Intracranial Arterial Diseases
Nervous System Diseases
Vascular Diseases
Dexmedetomidine
Sevoflurane
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Analgesics
Analgesics, Non-Narcotic
Anesthetics
Anesthetics, General
Anesthetics, Inhalation
Central Nervous System Agents
Central Nervous System Depressants
Hematologic Agents
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors

ClinicalTrials.gov processed this record on October 21, 2014